Pfizer, Inc. (NYSE:PFE) received a $39.00 target price from equities researchers at BMO Capital Markets in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 11.24% from the company’s previous close.

Other analysts also recently issued reports about the stock. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Finally, Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a report on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $38.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 EPS.

ILLEGAL ACTIVITY WARNING: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://theolympiareport.com/2017/11/02/pfizer-inc-pfe-given-a-39-00-price-target-by-bmo-capital-markets-analysts.html.

In other Pfizer news, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last three months, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at about $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer in the 1st quarter valued at about $121,000. 69.01% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.